Japara Healthcare
- Home ›
- AU ›
- Healthcare
Japara Healthcare Limited, together with its subsidiaries, owns, develops, and operates residential aged care facilities in Australia. The last earnings update was 111 days ago. More info.
Add to Portfolio Compare Print
JHC Share Price and Events
7 Day Returns
1 Year Returns
JHC Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Japara Healthcare (JHC) | 5.6% | -6.7% | -6.1% | -27.3% | -47% | -50.4% |
| AU Healthcare | 1.6% | 4.8% | 8.5% | 7.8% | -1.3% | 36.8% |
| AU Market | 1.5% | 4% | 5.5% | 5.1% | 24.8% | 12% |
1 Year Return vs Industry and Market
- JHC underperformed the Healthcare industry which returned 7.8% over the past year.
- JHC underperformed the Market in Australia which returned 5.1% over the past year.
JHC Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Japara Healthcare
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Japara Healthcare.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 5 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 7.7% |
| Perpetual Growth Rate | 10-Year AU Government Bond Rate | 2.3% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year AU Govt Bond Rate | 2.3% |
| Equity Risk Premium | S&P Global | 6% |
| Healthcare Unlevered Beta | Simply Wall St/ S&P Global | 0.64 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.638 (1 + (1- 30%) (50.51%)) |
0.908 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.91 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.31% + (0.908 * 5.96%) |
7.73% |
Discounted Cash Flow Calculation for ASX:JHC using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Japara Healthcare is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (AUD, Millions) | Source |
Present Value Discounted (@ 7.73%) |
|
|---|---|---|---|
| 2019 | 24.31 | Analyst x1 | 22.56 |
| 2020 | -21.56 | Analyst x1 | -18.58 |
| 2021 | 19.61 | Analyst x1 | 15.69 |
| 2022 | 151.69 | Analyst x1 | 112.64 |
| 2023 | 235.48 | Est @ 55.23% | 162.31 |
| 2024 | 328.15 | Est @ 39.36% | 209.96 |
| 2025 | 420.84 | Est @ 28.24% | 249.95 |
| 2026 | 506.96 | Est @ 20.46% | 279.51 |
| 2027 | 583.09 | Est @ 15.02% | 298.43 |
| 2028 | 648.44 | Est @ 11.21% | 308.07 |
| Present value of next 10 years cash flows | A$1,640.55 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= A$648.44 × (1 + 2.31%) ÷ (7.73% – 2.31%) |
A$12,253.24 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= A$12,253.24 ÷ (1 + 7.73%)10 |
A$5,821.47 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= A$1,640.55 + A$5,821.47 |
A$7,462.01 |
| Equity Value per Share (AUD) |
= Total value / Shares Outstanding
= A$7,462.01 / 267.25 |
A$27.92 |
| Calculation | Result | |
|---|---|---|
| Value per share (AUD) | From above. | A$27.92 |
| Current discount | Discount to share price of
A$1.32
= -1 x (A$1.32 - A$27.92) / A$27.92 |
95.3% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- Japara Healthcare's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Japara Healthcare's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Japara Healthcare's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Japara Healthcare's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in AUD | A$0.08 |
| ASX:JHC Share Price ** | ASX (2019-06-14) in AUD | A$1.32 |
| Australia Healthcare Industry PE Ratio | Median Figure of 24 Publicly-Listed Healthcare Companies | 16.97x |
| Australia Market PE Ratio | Median Figure of 545 Publicly-Listed Companies | 16.04x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Japara Healthcare.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = ASX:JHC Share Price ÷ EPS (both in AUD) = 1.32 ÷ 0.08 |
17.16x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Japara Healthcare is overvalued based on earnings compared to the AU Healthcare industry average.
- Japara Healthcare is overvalued based on earnings compared to the Australia market.
Price based on expected Growth
Does
Japara Healthcare's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 17.16x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts |
12.2%per year |
| Australia Healthcare Industry PEG Ratio | Median Figure of 18 Publicly-Listed Healthcare Companies | 1.91x |
| Australia Market PEG Ratio | Median Figure of 357 Publicly-Listed Companies | 1.4x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 17.16x ÷ 12.2% |
1.41x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Japara Healthcare is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on
Japara Healthcare's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in AUD | A$1.98 |
| ASX:JHC Share Price * | ASX (2019-06-14) in AUD | A$1.32 |
| Australia Healthcare Industry PB Ratio | Median Figure of 29 Publicly-Listed Healthcare Companies | 1.57x |
| Australia Market PB Ratio | Median Figure of 1,687 Publicly-Listed Companies | 1.65x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = ASX:JHC Share Price ÷ Book Value per Share (both in AUD) = 1.32 ÷ 1.98 |
0.67x |
* Primary Listing of Japara Healthcare.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Japara Healthcare is good value based on assets compared to the AU Healthcare industry average.
Value checks
We assess Japara Healthcare's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check) Japara Healthcare has a total score of 3/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
JHC Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Japara Healthcare's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
- Japara Healthcare's earnings growth is expected to exceed the Australia market average.
- Japara Healthcare's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| ASX:JHC Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts | 12.2% |
| ASX:JHC Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts | 10% |
| Australia Healthcare Industry Earnings Growth Rate | Market Cap Weighted Average | 10.6% |
| Australia Healthcare Industry Revenue Growth Rate | Market Cap Weighted Average | 6.4% |
| Australia Market Earnings Growth Rate | Market Cap Weighted Average | 7.1% |
| Australia Market Revenue Growth Rate | Market Cap Weighted Average | 3.3% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (5 months ago) | See Below |
| Future Estimates | Average of up to 5 Analyst Estimates (S&P Global) | See Below |
| Date (Data in AUD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2022-06-30 | 547 | 29 | 1 | |
| 2021-06-30 | 475 | 47 | 24 | 4 |
| 2020-06-30 | 430 | 43 | 21 | 5 |
| 2019-06-30 | 395 | 28 | 18 | 4 |
| Date (Data in AUD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 374 | 31 | 21 |
| 2018-09-30 | 368 | 33 | 22 |
| 2018-06-30 | 362 | 35 | 23 |
| 2018-03-31 | 360 | 32 | 24 |
| 2017-12-31 | 358 | 29 | 25 |
| 2017-09-30 | 356 | 31 | 28 |
| 2017-06-30 | 354 | 32 | 30 |
| 2017-03-31 | 351 | 35 | 29 |
| 2016-12-31 | 348 | 38 | 29 |
| 2016-09-30 | 337 | 37 | 30 |
| 2016-06-30 | 325 | 37 | 30 |
| 2016-03-31 | 311 | 38 | 30 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (5 months ago) | See Below |
| Future Estimates | Average of up to 5 Analyst Estimates (S&P Global) | See Below |
All data from Japara Healthcare Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in AUD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2022-06-30 | 0.11 | 0.11 | 0.11 | 1.00 |
| 2021-06-30 | 0.09 | 0.11 | 0.08 | 5.00 |
| 2020-06-30 | 0.08 | 0.09 | 0.07 | 5.00 |
| 2019-06-30 | 0.07 | 0.07 | 0.06 | 5.00 |
| Date (Data in AUD Millions) | EPS * |
|---|---|
| 2018-12-31 | 0.08 |
| 2018-09-30 | 0.08 |
| 2018-06-30 | 0.09 |
| 2018-03-31 | 0.09 |
| 2017-12-31 | 0.10 |
| 2017-09-30 | 0.10 |
| 2017-06-30 | 0.11 |
| 2017-03-31 | 0.11 |
| 2016-12-31 | 0.11 |
| 2016-09-30 | 0.11 |
| 2016-06-30 | 0.12 |
| 2016-03-31 | 0.11 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess Japara Healthcare's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Japara Healthcare has a total score of 3/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
JHC Past Performance
How has Japara Healthcare performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Japara Healthcare's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.
- Japara Healthcare's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Japara Healthcare's 1-year earnings growth is negative, it can't be compared to the AU Healthcare industry average.
Earnings and Revenue History
All data from Japara Healthcare Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in AUD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 374.26 | 20.60 | 35.15 | |
| 2018-09-30 | 367.89 | 21.96 | 33.42 | |
| 2018-06-30 | 361.52 | 23.33 | 31.69 | |
| 2018-03-31 | 359.51 | 24.34 | 29.88 | |
| 2017-12-31 | 357.50 | 25.36 | 28.07 | |
| 2017-09-30 | 355.75 | 27.54 | 27.80 | |
| 2017-06-30 | 354.00 | 29.71 | 27.52 | |
| 2017-03-31 | 351.17 | 29.25 | 27.27 | |
| 2016-12-31 | 348.33 | 28.80 | 27.02 | |
| 2016-09-30 | 336.80 | 29.59 | 25.84 | |
| 2016-06-30 | 325.28 | 30.38 | 24.65 | |
| 2016-03-31 | 310.96 | 29.81 | 23.50 | |
| 2015-12-31 | 296.64 | 29.24 | 22.34 | |
| 2015-09-30 | 287.45 | 29.04 | 21.52 | |
| 2015-06-30 | 278.26 | 28.84 | 20.70 | |
| 2014-06-30 | 193.51 | -11.75 | 14.63 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- Japara Healthcare has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Japara Healthcare used its assets less efficiently than the AU Healthcare industry average last year based on Return on Assets.
- Japara Healthcare's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
Past performance checks
We assess Japara Healthcare's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Japara Healthcare has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
JHC Health
How is Japara Healthcare's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Japara Healthcare's finances.
The net worth of a company is the difference between its assets and liabilities.
- Japara Healthcare's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Japara Healthcare's long term commitments exceed its cash and other short term assets.
Balance sheet
Assets
Liabilities and shares
- High level of physical assets or inventory.
- Debt is not covered by short term assets, assets are 0.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Japara Healthcare Company Filings, last reported 5 months ago.
| Date (Data in AUD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 532.94 | 177.50 | 45.65 |
| 2018-09-30 | 532.94 | 177.50 | 45.65 |
| 2018-06-30 | 533.78 | 145.50 | 29.16 |
| 2018-03-31 | 533.78 | 145.50 | 29.16 |
| 2017-12-31 | 531.12 | 86.00 | 61.62 |
| 2017-09-30 | 531.12 | 86.00 | 61.62 |
| 2017-06-30 | 535.71 | 61.00 | 41.38 |
| 2017-03-31 | 535.71 | 61.00 | 41.38 |
| 2016-12-31 | 534.43 | 71.00 | 63.23 |
| 2016-09-30 | 534.43 | 71.00 | 63.23 |
| 2016-06-30 | 532.31 | 59.50 | 24.57 |
| 2016-03-31 | 532.31 | 59.50 | 24.57 |
| 2015-12-31 | 532.51 | 46.80 | 45.81 |
| 2015-09-30 | 532.51 | 46.80 | 45.81 |
| 2015-06-30 | 530.04 | 0.00 | 53.88 |
| 2014-06-30 | 513.99 | 15.82 | 28.11 |
- Japara Healthcare's level of debt (33.3%) compared to net worth is satisfactory (less than 40%).
- Unable to establish if Japara Healthcare's debt level has increased without past 5-year debt data.
- Debt is not well covered by operating cash flow (17.4%, less than 20% of total debt).
- Interest payments on debt are well covered by earnings (EBIT is 4.5x coverage).
Financial health checks
We assess Japara Healthcare's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Japara Healthcare has a total score of 2/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
JHC Dividends
What is Japara Healthcare's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
A$2,000 of
Japara Healthcare
shares you are expected to receive
A$85
in your first year as a dividend.
Dividend Amount
- Japara Healthcare's pays a higher dividend yield than the bottom 25% of dividend payers in Australia (2.68%).
- Japara Healthcare's dividend is below the markets top 25% of dividend payers in Australia (5.71%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 5 Analyst Estimates (S&P Global) | See Below |
| Australia Healthcare Industry Average Dividend Yield | Market Cap Weighted Average of 22 Stocks | 2.9% |
| Australia Market Average Dividend Yield | Market Cap Weighted Average of 415 Stocks | 4.1% |
| Australia Minimum Threshold Dividend Yield | 10th Percentile | 1.6% |
| Australia Bottom 25% Dividend Yield | 25th Percentile | 2.7% |
| Australia Top 25% Dividend Yield | 75th Percentile | 5.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in A$) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2022-06-30 | 0.11 | 1.00 |
| 2021-06-30 | 0.08 | 5.00 |
| 2020-06-30 | 0.07 | 5.00 |
| 2019-06-30 | 0.06 | 5.00 |
| Date (Data in A$) | Dividend per share (annual) | Avg. Yield (%) |
|---|---|---|
| 2019-02-25 | 0.056 | 3.974 |
| 2018-08-27 | 0.078 | 6.173 |
| 2018-02-26 | 0.098 | 5.165 |
| 2017-08-28 | 0.113 | 5.811 |
| 2017-02-27 | 0.113 | 5.540 |
| 2016-08-22 | 0.115 | 5.644 |
| 2016-02-16 | 0.115 | 4.199 |
| 2015-08-24 | 0.110 | 3.700 |
| 2015-02-26 | 0.110 | 4.109 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Japara Healthcare has been paying a dividend for less than 10 years and during this time payments have been volatile (annual drop of over 20%).
- Japara Healthcare has only been paying a dividend for 4 years, and since then dividends per share have fallen.
Income/ dividend checks
We assess Japara Healthcare's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Japara Healthcare afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Japara Healthcare has a total score of 2/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
JHC Management
CEO
| COMPENSATION | A$1,012,000 |
CEO Bio
Mr. Andrew Sudholz, also known as Mark, FPI, MAICD, serves as the Chief Executive Officer and Executive Director of JAPARA Holdings Pty Ltd. Mr. Sudholz serves as the Chief Executive Officer and Managing Director of Japara Healthcare Limited and has been its Executive Director since March 19, 2014. He served as Managing Partner of Ernst & Young LLP. He has experience in the real estate, healthcare and professional services industries. Prior to joining Japara, he was a Global Partner of Arthur Andersen Group, a national partner of Ernst & Young Real Estate Advisory Services Group and the state general manager of the Triden Corporation. He is a National Board Member of the Property Council of Australia and is a Member of the Australian Institute of Company Directors. Mr. Sudholz holds an Associate Diploma of Valuations from the Royal Melbourne Institution of Technology. He holds FPI & MAICD. He was president of the Victorian division.
CEO Compensation
- Mark's compensation has been consistent with company performance over the past year, both up more than 20%.
- Mark's remuneration is higher than average for companies of similar size in Australia.
Management Team
Mark Sudholz
MD, CEO & Executive Director
A$1M
Chris Price
CFO & Company Secretary
A$546K
53
4 yrs
Ashley van Winkel
Group Executive of People & Infrastructure
A$70K
Wendy Waddell
Group Executive of Care & Commercial
Bruce Paterson
Company Secretary
3.5 yrs
Board of Directors Tenure
Average tenure and age of the Japara Healthcare board of directors in years:
- The tenure for the Japara Healthcare board of directors is about average.
Board of Directors
Linda Nicholls
Non-Executive Chairman
A$250K
70
Mark Sudholz
MD, CEO & Executive Director
A$1M
5.3 yrs
Richard Anthony England
Non-Executive Director
A$125K
68
5.3 yrs
David Blight
Non Executive Director
A$125K
55
5.3 yrs
JoAnne Stephenson
Independent Non-Executive Director
A$125K
3.8 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (A$) | Value (A$) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 11. Jun 19 | Sell | Perpetual Limited | Company | 11. Sep 18 | 30. Oct 18 | -468,984 | A$1.73 | A$-612,234 | ||
| 11. Jun 19 | Buy | Perpetual Limited | Company | 13. Sep 18 | 06. Jun 19 | 3,285,777 | A$1.75 | A$4,114,732 | ||
| 19. May 19 | Sell | Dimensional Fund Advisors L.P. | Company | 16. Jan 19 | 11. Feb 19 | -197,814 | A$1.32 | A$-245,019 | ||
| 19. May 19 | Buy | Dimensional Fund Advisors L.P. | Company | 16. Jan 19 | 16. May 19 | 1,109,017 | A$1.53 | A$1,510,587 | ||
| 17. Apr 19 | Buy | Pendal Group Limited | Company | 02. Apr 19 | 15. Apr 19 | 2,441,232 | A$1.44 | A$3,492,183 | ||
| 15. Mar 19 | Sell | Pendal Group Limited | Company | 30. Jan 19 | 05. Mar 19 | -216,264 | A$1.39 | A$-295,023 | ||
| 15. Mar 19 | Buy | Pendal Group Limited | Company | 30. Oct 18 | 12. Mar 19 | 4,373,570 | A$1.36 | A$5,930,659 | ||
| 13. Mar 19 | Buy | Linda Nicholls | Individual | 11. Mar 19 | 11. Mar 19 | 2,956 | A$1.36 | A$4,020 | ||
| 13. Mar 19 | Buy | Richard Anthony England | Individual | 11. Mar 19 | 11. Mar 19 | 1,273 | A$1.36 | A$1,731 | ||
| 04. Mar 19 | Buy | Linda Nicholls | Individual | 28. Feb 19 | 28. Feb 19 | 11,300 | A$1.32 | A$14,965 | ||
| 14. Dec 18 | Buy | Linda Nicholls | Individual | 10. Dec 18 | 10. Dec 18 | 6,870 | A$1.17 | A$8,038 | ||
| 14. Dec 18 | Buy | Richard Anthony England | Individual | 10. Dec 18 | 10. Dec 18 | 2,959 | A$1.17 | A$3,462 | ||
| 08. Nov 18 | Buy | Linda Nicholls | Individual | 05. Nov 18 | 05. Nov 18 | 20,000 | A$1.24 | A$24,864 | ||
| 19. Sep 18 | Buy | Pendal Group Limited | Company | 27. Feb 18 | 17. Sep 18 | 5,432,120 | A$1.80 | A$9,726,254 | ||
| 17. Sep 18 | Sell | Dimensional Fund Advisors L.P. | Company | 16. Jun 18 | 31. Jul 18 | -42,782 | A$1.77 | A$-75,911 | ||
| 17. Sep 18 | Buy | Dimensional Fund Advisors L.P. | Company | 10. Jul 18 | 13. Sep 18 | 490,920 | A$1.93 | A$895,264 | ||
| 09. Sep 18 | Buy | JoAnne Stephenson | Individual | 05. Sep 18 | 05. Sep 18 | 12,000 | A$1.78 | A$21,360 | ||
| 07. Sep 18 | Buy | Perpetual Limited | Company | 04. Sep 18 | 04. Sep 18 | 1,367,087 | A$1.79 | A$2,445,663 | ||
| 06. Sep 18 | Buy | Linda Nicholls | Individual | 03. Sep 18 | 03. Sep 18 | 17,467 | A$1.79 | A$31,249 | ||
| 31. Aug 18 | Sell | Perpetual Limited | Company | 15. Aug 18 | 27. Aug 18 | -284,705 | A$1.85 | A$-521,205 | ||
| 31. Aug 18 | Buy | Perpetual Limited | Company | 28. Aug 18 | 29. Aug 18 | 1,349,767 | A$1.78 | A$2,384,899 | ||
| 10. Aug 18 | Sell | Perpetual Limited | Company | 05. Jul 18 | 08. Aug 18 | -338,374 | A$1.87 | A$-628,983 | ||
| 10. Jul 18 | Sell | Dimensional Fund Advisors L.P. | Company | 13. Jun 18 | 25. Jun 18 | -15,370 | A$1.84 | A$-28,263 | ||
| 10. Jul 18 | Buy | Dimensional Fund Advisors L.P. | Company | 09. Mar 18 | 09. Jul 18 | 1,204,345 | A$1.98 | A$2,277,050 | ||
Management checks
We assess Japara Healthcare's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Japara Healthcare has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
JHC News
Simply Wall St News
Could The Japara Healthcare Limited (ASX:JHC) Ownership Structure Tell Us Something Useful?
With a market capitalization of AU$369m, Japara Healthcare is a small cap stock, so it might not be well known by many institutional investors. … View our latest analysis for Japara Healthcare ASX:JHC Ownership Summary, June 4th 2019 What Does The Institutional Ownership Tell Us About Japara Healthcare? … Insider Ownership Of Japara Healthcare The definition of company insiders can be subjective, and does vary between jurisdictions.
Simply Wall St - – Full articleIs Japara Healthcare Limited (ASX:JHC) An Attractive Dividend Stock?
Dividend paying stocks like Japara Healthcare Limited (ASX:JHC) tend to be popular with investors, and for good reason - some research suggests a significant amount of all stock market returns come from reinvested dividends. … Payout ratios Companies (usually) pay dividends out of their earnings. If a company is paying more than it earns, the dividend might have to be cut. So we need to be form a view on if a company's dividend is sustainable, relative to its net profit after tax. In the last year, Japara Healthcare paid out 85% of its profit as dividends. Paying out a majority of its earnings limits the amount that can be reinvested in the business. This may indicate a commitment to paying a dividend, or a dearth of investment opportunities. We also measure dividends paid against a company's levered free cash flow, to see if enough cash was generated to cover the dividend. Unfortunately, while Japara Healthcare pays a dividend, it also reported negative free cash flow last year. While there may be a good reason for this, it's not ideal from a dividend perspective. Is Japara Healthcare's Balance Sheet Risky? As Japara Healthcare has a meaningful amount of debt, we need to check its balance sheet to see if the company might have debt risks. A rough way to check this is with these two simple ratios: a) net debt divided by EBITDA (earnings before interest, tax, depreciation and amortisation), and b) net interest cover. … Japara Healthcare has been paying a dividend for the past four years.
Simply Wall St - – Full articleShould You Worry About Japara Healthcare Limited's (ASX:JHC) CEO Salary Level?
See our latest analysis for Japara Healthcare How Does Mark Sudholz's Compensation Compare With Similar Sized Companies? … It would therefore appear that Japara Healthcare Limited pays Mark Sudholz more than the median CEO remuneration at companies of a similar size, in the same market. … We compared the total CEO remuneration paid by Japara Healthcare Limited, and compared it to remuneration at a group of similar sized companies.
Simply Wall St - – Full articleJapara Healthcare Limited’s (ASX:JHC) Investment Returns Are Lagging Its Industry
To be precise, we'll consider its Return On Capital Employed (ROCE), as that will inform our view of the quality of the business. … Return On Capital Employed (ROCE): What is it? … ROCE measures the amount of pre-tax profits a company can generate from the capital employed in its business.
Simply Wall St - – Full articleIs Japara Healthcare Limited (ASX:JHC) Potentially Undervalued?
Japara Healthcare Limited (ASX:JHC), which is in the healthcare business, and is based in Australia,. … With many analysts covering the stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price? … Let’s take a look at Japara Healthcare’s outlook and value based on the most recent financial data to see if the opportunity still exists
Simply Wall St - – Full articleIs Japara Healthcare Limited (ASX:JHC) Overpaying Its CEO?
First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Mark Sudholz's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that Japara Healthcare Limited has a market cap of AU$387m, and is paying total annual CEO compensation of AU$1.0m.
Simply Wall St - – Full articleJapara Healthcare Limited (ASX:JHC): Is Growth Priced In?
Growth expectations for Japara Healthcare Limited (ASX:JHC) are high, but many investors are starting to ask whether its last close at A$1.46 can still be rationalized by the future potential. … View our latest analysis for Japara Healthcare? … Investors in Japara Healthcare have been patiently waiting for the uptick in earnings.
Simply Wall St - – Full articleRead This Before You Buy Japara Healthcare Limited (ASX:JHC) Because Of Its P/E Ratio
We'll look at Japara Healthcare Limited's (ASX:JHC) P/E ratio and reflect on what it tells us about the company's share price. … Based on the last twelve months, Japara Healthcare's P/E ratio is 18.27. … Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)
Simply Wall St - – Full articleWhy You Should Care About Japara Healthcare Limited’s (ASX:JHC) Cash Levels
What is left after investment, determines the value of the stock since this cash flow technically belongs to investors of the company. … I will take you through Japara Healthcare’s cash flow health and the risk-return concept based on the stock’s cash flow yield, using the most recent financial data. … Japara Healthcare’s free cash flow (FCF) is the level of cash flow the business generates from its operational activities, after it reinvests in the company as capital expenditure.
Simply Wall St - – Full articleInvestors Who Bought Japara Healthcare Shares Three Years Ago Are Now Down 60%
Long term Japara Healthcare Limited (ASX:JHC) shareholders know that all too well, since the share price is down considerably over three years. … Sadly for them, the share price is down 60% in that time. … In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business.
Simply Wall St - – Full articleJHC Company Info
Description
Japara Healthcare Limited, together with its subsidiaries, owns, develops, and operates residential aged care facilities in Australia. It operates approximately 5,400 resident places across 48 homes located in Victoria, New South Wales, Queensland, South Australia, and Tasmania; and 180 independent living units across 5 retirement villages. The company was founded in 2005 and is based in Southbank, Australia.
Details
| Name: | Japara Healthcare Limited |
| JHC | |
| Exchange: | ASX |
| Founded: | 2005 |
| A$351,430,236 | |
| 267,247,328 | |
| Website: | http://japara.com.au |
| Address: |
Japara Healthcare Limited Q1 Building, Level 4, Southbank, Victoria, 3006, Australia |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| ASX | JHC | Ordinary Shares | Australian Securities Exchange | AU | AUD | 17. Apr 2014 | |
| DB | 7JH | Ordinary Shares | Deutsche Boerse AG | DE | EUR | 17. Apr 2014 |
Number of employees
Current staff
Industry
| Health Care Facilities | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/06/15 10:35 |
| End of day share price update: | 2019/06/14 00:00 |
| Last estimates confirmation: | 2019/05/24 |
| Last earnings filing: | 2019/02/24 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/06/30 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
